I
Immunomic Therapeutics
Immunomic Therapeutics, Inc.
About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-owned biotechnology company that operates in the clinical stage. The company is at the forefront of exploring nucleic acid immunotherapy platforms, which are technologies that could change the way we use immunotherapy for cancer, allergies, and animal health. Immunotherapy is a type of treatment that uses our body's immune system to fight diseases. ITI's mission is to develop vaccines that can transform lives.
Read full description
The company's investigational UNITE® platform is a combination of various technologies and capabilities. This includes ITI’s proprietary lysosomal targeting technology, which is currently being used in two Phase I clinical trials as a cancer immunotherapy. Lysosomal targeting technology is a method that directs the immune response to the lysosome, a part of our cells, to enhance the immune response against diseases.
ITI's nucleic acid vaccines have the potential to use the body's natural biochemistry to develop a broad immune response. This could place the UNITE® platform at the intersection of immunotherapies for various illnesses, including cancer, allergy, and infectious diseases.
The company's business model revolves around the development and clinical testing of these vaccines, with the aim to commercialize them once they have proven to be safe and effective. ITI's primary clients are patients diagnosed with diseases like cancer, who could benefit from their immunotherapy treatments.
Recently, ITI reported positive results from its Phase 1 Clinical Trial in patients diagnosed with Merkel Cell Carcinoma, a rare type of skin cancer. This indicates that their ITI-3000 treatment has a favorable safety and tolerability profile.
At a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Rockville, United States
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 37.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, DNA, Vaccines, Genetics and genomics, Disease, Biotech and Pharma, Hard Tech, medical testing
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Apr 2020 | $61M | $245M | Undisclosed | ↗ |
| EARLY VCOther financing | Nov 2015 | $0 | — | Keiretsu Forum Northwest | — |
Growth signals
Latest recorded traffic for Immunomic Therapeutics is 2.6K monthly website visits, up 18.2% over the last three months. Immunomic Therapeutics's team grew 4.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Mid Atlantic Bio Angels
Keiretsu Forum Northwest
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immunomic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immunomic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.